Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups
about
Impact of endofungal bacteria on infection biology, food safety, and drug developmentTubulin-interactive natural products as anticancer agentsStabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?A total synthesis of the antitumour macrolide rhizoxin DA gene cluster encoding rhizoxin biosynthesis in "Burkholderia rhizoxina", the bacterial endosymbiont of the fungus Rhizopus microsporus.The impact of plant-pathogen studies on medicinal drug discovery.Toward a Cancer Drug of Fungal OriginBacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosisBiosynthesis of polyketides by trans-AT polyketide synthases.Biosynthesis of polyketides by trans-AT polyketide synthases.Antiproliferative effects of ester- and amide-functionalized rhizoxin derivatives.Total synthesis of the tubulin inhibitor WF-1360F based on macrocycle formation through ring-closing alkyne metathesis.Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold.
P2860
Q21089611-D27F115D-F39F-4DA2-B25D-D821CBB4EEE4Q24650163-751707C5-150F-4353-A380-304880AD2121Q26781365-E93269E3-09FC-43C2-81B2-D9C48C36A233Q28285115-8A306D52-18BB-4769-873A-05422304E1B0Q33265857-0CF4A463-7899-4862-84A9-15CEA8B0C172Q34147144-16B21ECA-30DD-4B11-BF36-9D7646CC82D5Q35596957-AC4E4AF9-F5D2-4425-B471-6BCE3955821CQ37312187-18CCB326-1B9F-4A11-82F2-7D3F2BC2F054Q37750498-EB45F8BB-E3C5-4319-A86E-F9FBFDBA3EC1Q38675125-AB5523F2-1592-4DCA-BE0B-1625252040E6Q39459728-6260F184-BBE4-405E-92C4-330542DA52C4Q46179864-2B61094D-D745-4B21-A92D-B6A7C2C0E52CQ52769257-CE70BBF0-A083-4213-AAD4-5948D9BAB2B6
P2860
Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups
description
1996 nî lūn-bûn
@nan
1996 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Multicentre phase II pharmacol ...... cular mechanisms (PAMM) groups
@ast
Multicentre phase II pharmacol ...... cular mechanisms (PAMM) groups
@en
Multicentre phase II pharmacol ...... cular mechanisms (PAMM) groups
@nl
type
label
Multicentre phase II pharmacol ...... cular mechanisms (PAMM) groups
@ast
Multicentre phase II pharmacol ...... cular mechanisms (PAMM) groups
@en
Multicentre phase II pharmacol ...... cular mechanisms (PAMM) groups
@nl
prefLabel
Multicentre phase II pharmacol ...... cular mechanisms (PAMM) groups
@ast
Multicentre phase II pharmacol ...... cular mechanisms (PAMM) groups
@en
Multicentre phase II pharmacol ...... cular mechanisms (PAMM) groups
@nl
P2093
P2860
P356
P1476
Multicentre phase II pharmacol ...... cular mechanisms (PAMM) groups
@en
P2093
A Setanoians
B Heinrich
D J Wagener
H L McLeod
L S Murray
M A Graham
N Pavlidis
P2860
P2888
P304
P356
10.1038/BJC.1996.657
P407
P577
1996-12-01T00:00:00Z
P5875
P6179
1020791898